p53 expression as a prognostic determinant in resected distal bile duct carcinoma

A. M. Rijken, G. J A Offerhaus, M. M. Polak, D. J. Gouma, T. M. Van Gulik

Research output: Contribution to journalArticle

Abstract

Aims: To determine the incidence and prognostic value of p53 immunopositivity in resectable distal bile duct carcinoma (DBDC). Methods: Forty-seven paraffin-embedded archival tumour samples of patients with DBDC, who underwent subtotal pancreatoduodenectomy from 1985 to 1996, were immunohistochemically examined for p53 positivity, using the anti-p53 antibody D07. Results: Nineteen (40%) of the 47 tumours demonstrated positive (> 30%) p53 protein immunostaining. Focally positive or negative staining was seen in the remaining 28 (60%) cases. Patients in this low p53 category survived significantly longer than those in the high p53 category, with median survival durations of 29 and 13 months respectively (P = 0.039). p53 positivity was independent of age, sex, tumour size, radicality of resection, histopathological grading, lymph-node status, perineural invasion and vasoinvasive growth. Conclusions: This study indicates that low (0-30%) p53 expression is a favourable prognostic factor in patients with resected DBDC.

Original languageEnglish (US)
Pages (from-to)297-301
Number of pages5
JournalEuropean Journal of Surgical Oncology
Volume25
Issue number3
DOIs
StatePublished - Jun 1999
Externally publishedYes

Keywords

  • Biliary cancer
  • Immunohistochemistry
  • p53
  • Prognosis

ASJC Scopus subject areas

  • Oncology
  • Surgery

Fingerprint Dive into the research topics of 'p53 expression as a prognostic determinant in resected distal bile duct carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Rijken, A. M., Offerhaus, G. J. A., Polak, M. M., Gouma, D. J., & Van Gulik, T. M. (1999). p53 expression as a prognostic determinant in resected distal bile duct carcinoma. European Journal of Surgical Oncology, 25(3), 297-301. https://doi.org/10.1053/ejso.1998.0645